本帖最后由 老马 于 2012-1-13 21:20 编辑 $ e0 n1 h: I1 b( G* M: B" h
+ @2 D& i7 }$ L6 e( j7 Z
爱必妥和阿瓦斯丁的比较 ?& U6 W; n* ~5 ?# v& C
5 J' q9 v8 H5 n _: K" Z) ?9 phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 G! u. I0 {; I" A* R& T3 A
; N+ w9 G; @3 ~! L( u
# A/ K% t" @ t8 g' jhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/6 c* T x1 s; d3 O
==================================================6 N. _0 C: n9 I( u! [6 d1 \ t! ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
8 L& [6 p* _; P2 MPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. m* `0 B/ H; Q2 h0 X
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." j# U6 o4 v# k; r
|